PetCaseFinder

Peer-reviewed veterinary case report

Kv 11.1 Protein Linked to Malignancy in Dog Mammary Tumors

By Lee, Nuri et al.·Published in In vivo (Athens, Greece)·2024·Department of Veterinary Clinical Science, South Korea·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Kv 11.1 Expression Is Associated With Malignancy of Canine Mammary Gland Tumors.

Species:
dog
Canine mammary tumorsBehaviour & energyDogs

Plain-English summary

A study looked at 57 samples of mammary gland tumors from female dogs to see how a specific protein, Kv 11.1, was related to the tumors' severity. It was found that benign tumors had higher levels of Kv 11.1 compared to malignant ones, suggesting that lower levels of this protein might indicate a more aggressive cancer. This finding could help veterinarians assess the seriousness of a tumor and guide treatment decisions. Understanding Kv 11.1 levels may improve how we manage canine mammary gland tumors in the future.

People also search for: dog mammary tumor treatment · canine breast cancer prognosis · Kv 11.1 in dog tumors

Abstract

BACKGROUND/AIM: The expression level of the voltage-dependent potassium channel Kv 11.1 was shown to be associated with the clinicopathological features, aggressiveness, and prognosis of human breast cancer. Canine mammary gland tumor (cMGT) is the most common tumor type in intact female dogs; however, the significance of Kv 11.1 in cMGT is unknown. The aim of this study was to identify Kv 11.1 expression in 57 benign and malignant cMGT tissues from dogs and to investigate the correlation of Kv 11.1 expression with the clinicopathological parameters and prognosis of cMGT. MATERIALS AND METHODS: A total of 57 samples were collected from cMGTs surgically resected at the Veterinary Medical Teaching Hospital, Seoul National University and subjected to immunohistochemistry assay using rabbit anti-Kv 11.1 polyclonal antibody. Immunohistochemical staining results were evaluated as the sum of intensity and percentage scores. The correlation between immunohistochemistry scores and clinicopathological parameters was investigated. RESULTS: Immunohistochemical analysis revealed that Kv 11.1 immunoreactivity was higher in benign cMGTs than in malignant cMGTs. Kv 11.1 expression was significantly associated with tumor malignancy (p<0.001), tumor size (p<0.001), histological grade (p<0.05), and age at the time of mastectomy (p<0.05). CONCLUSION: This study presents the first evidence of Kv 11.1 expression in cMGTs and indicates an inverse correlation between Kv 11.1 expression and tumor malignancy. Kv 11.1 expression can be used as a prognostic biomarker and a tool for the management of cMGTs.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38418114/